We proceeded to explore whether there were any correlations between plasma versican or plasma exosomal versican levels and distant metastases (e.g., brain, bone) or mutation(e.g., EGFR, ALK) in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.